Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 10/20 | 0.91 |
| ▸ | MEN1 | O00255 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16365889 | 0.95 | KIT (1.00) | KITMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL16365883 | 0.94 | KIT (1.00) | KITMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL16321030 | 0.85 | KIT (1.00) | KITMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL16365885 | 0.84 | KIT (0.95) | KITNPC1 | |
| SCHEMBL16365886 | 0.82 | KIT (1.00) | KITMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL17782803 | 0.81 | KIT (0.95) | KITMEN1KMT2ANPC1 | |
| SCHEMBL16365888 | 0.81 | KIT (1.00) | KITMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL23554025 | 0.78 | VCP (0.65) | KITMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL206252 | 0.78 | KIT (0.71) | KITMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL16320951 | 0.77 | KIT (0.68) | KITMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | KIT, CHUK, CSNK1E | KIT 1/4885MEN1 3086/4885KMT2A 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.